# A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

> **NCT04203719** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 140 (estimated)

## Conditions studied

- Advanced Head, Neck and Chest Cancer

## Interventions

- **DRUG:** AK105
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04203719
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-09
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-05-30
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2020-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04203719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04203719, "A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04203719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*